Mineralys Grants Inducement Awards to Two New Hires

Mineralys Therapeutics, a biopharmaceutical firm developing treatments for hypertension and aldosterone-related conditions, announced the grant of inducement equity awards to two new non-executive employees. The company disclosed these actions on September 8, 2026, in compliance with Nasdaq Listing Rule 5635(c)(4), which permits specific equity grants to new hires without shareholder approval.

The awards consist of stock options covering 29,760 shares and restricted stock units covering 22,320 shares. These grants were made under the company’s 2025 Employment Inducement Incentive Award Plan, a vehicle designed to facilitate the recruitment of new personnel by offering immediate equity incentives tied to long-term service.

Vesting schedules align with four-year retention goals

Both the option and RSU awards are structured with a four-year vesting period to ensure long-term alignment between the new employees and the company’s strategic objectives. For the stock options, 25% of the underlying shares vest on the first anniversary of the commencement date, September 8, 2026. The remaining balance vests monthly over the subsequent 47 months, provided the employees maintain continuous service.

The restricted stock units follow a similar four-year timeline but utilize an annual vesting schedule. Under this structure, 25% of the RSU shares vest on each of the first four anniversaries of the start date. This staggered approach ties a significant portion of the compensation to multi-year performance and retention, reducing the risk of immediate liquidity events for the recipients.

Regulatory framework supports flexible hiring practices

Mineralys utilized Nasdaq Listing Rule 5635(c)(4) to execute these grants, a provision that allows companies to issue equity to new employees as an inducement to enter employment. This regulatory pathway is critical for biotech firms like Mineralys, which operate in capital-intensive environments and require the ability to attract specialized talent quickly without the delays associated with shareholder voting processes.

As reported by GN stocks/nasdaq, this move underscores the company’s ongoing effort to build its organizational capacity. By leveraging specific listing rule exemptions, Mineralys maintains flexibility in its compensation strategies, ensuring it can compete for key non-executive roles while adhering to exchange listing standards and corporate governance requirements.

Company focus remains on aldosterone inhibition

Mineralys continues to concentrate its resources on developing lorundrostat, an investigational oral aldosterone synthase inhibitor. The company targets diseases driven by dysregulated aldosterone, including chronic kidney disease and obstructive sleep apnea. The recruitment of new non-executive staff through these inducement awards supports the operational infrastructure necessary to advance these therapeutic candidates toward clinical milestones.